At the time of writing, Neurocrine Biosciences, Inc [NBIX] stock is trading at $143.03, up 1.51%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NBIX shares have gain 3.57% over the last week, with a monthly amount glided 10.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on August 29, 2024, and elevated its price target to $159. On April 24, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Deutsche Bank initiated its recommendation with a Buy and recommended $136 as its price target on December 12, 2023. In a note dated August 21, 2023, Mizuho reiterated an Neutral rating on this stock and boosted its target price from $112 to $113.
For the past year, the stock price of Neurocrine Biosciences, Inc fluctuated between $110.95 and $157.98. Currently, Wall Street analysts expect the stock to reach $155 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $143.03 at the most recent close of the market. An investor can expect a potential return of 8.37% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
According to Neurocrine Biosciences, Inc [NASDAQ:NBIX], the company’s sales were 2.24B for trailing twelve months, which represents an 24.72% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.16 and Total Capital is 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 139.66 points at the first support level, and at 136.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 145.20, and for the 2nd resistance point, it is at 147.37.
Ratios To Look Out For
It is important to note that Neurocrine Biosciences, Inc [NASDAQ:NBIX] has a current ratio of 4.37. In addition, the Quick Ratio stands at 4.26 and the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 6.46, the price to book ratio is 5.32 and price to earnings (TTM) ratio is 38.32.
Transactions by insiders
Recent insider trading involved Delaet Ingrid, Chief Regulatory Officer, that happened on Dec 31 ’24 when 272.0 shares were sold. Officer, INGRID DELAET completed a deal on Dec 31 ’24 to buy 272.0 shares. Meanwhile, Chief Regulatory Officer Delaet Ingrid sold 1091.0 shares on Dec 17 ’24.
